The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection

  • K. Domagalski
  • M. Pawłowska
  • A. Zaleśna
  • M. Tyczyno
  • M. Skorupa-Kłaput
  • A. Tretyn
  • W. Halota
Article

Abstract

The impact of interleukin 28B (IL-28B) on the results of interferon (IFN)-based therapy in patients chronically infected with hepatitis B virus (HBV) is poorly understood. The aim of this study was to evaluate the relationship between IL-28B markers and the response to IFN monotherapy in Polish patients with anti-hepatitis B e (HBe)-positive chronic hepatitis B (CHB). We determined three single-nucleotide polymorphisms (SNPs) of IL-28B (rs12979860, rs12980275, and rs8099917) in 86 patients who were treated with pegylated interferon (PEG-IFN) for 48 weeks. The effectiveness of the therapy was evaluated based on the virological and biochemical response. The primary efficacy parameters were the HBV DNA viral load below 400 IU/ml and 2,000 IU/ml in combination with alanine aminotransferase (ALT) normalization (<40 IU/l), measured 24 weeks after the treatment. Viral load below 400 IU/ml or 2,000 IU/ml with ALT normalization was achieved by 37 % and 46 % of patients, respectively. It has been shown that the distribution of IL-28B genotypes in the dominant genetic model in patients with different therapeutic success differ significantly only for rs12979860. The IL-28B rs12979860 CC genotype was associated with lower treatment success [odds ratio (OR), 0.31; p = 0.025 and OR, 0.37; p = 0.044 for <400 IU/ml HBV DNA with <40 IU/l ALT, and <2,000 IU/ml HBV DNA with <40 IU/l ALT, respectively]. However, in the conditional logistic regression analysis adjusted by factors associated with combined response, rs12979860 was significantly associated only with <400 IU/ml HBV DNA with <40 IU/l ALT (OR, 0.24; p = 0.026). IL-28B polymorphisms have prognostic significance in assessing the treatment effectiveness based on the virological and biochemical response of patients with anti-HBe-positive CHB.

References

  1. 1.
    Chan HL, Sung JJ (2006) Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26(2):153–161PubMedCrossRefGoogle Scholar
  2. 2.
    Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351(12):1206–1217PubMedCrossRefGoogle Scholar
  3. 3.
    Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A (2010) Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53(2):348–356PubMedCrossRefGoogle Scholar
  4. 4.
    Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL (2008) Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 28(9):1067–1077PubMedCrossRefGoogle Scholar
  5. 5.
    Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45(2):507–539PubMedCrossRefGoogle Scholar
  6. 6.
    Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50(3):661–662PubMedCrossRefGoogle Scholar
  7. 7.
    Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group (2013) Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 62(2):290–298PubMedCrossRefGoogle Scholar
  8. 8.
    Manesis EK, Hadziyannis SJ (2001) Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121(1):101–109PubMedCrossRefGoogle Scholar
  9. 9.
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26):2682–2695PubMedCrossRefGoogle Scholar
  10. 10.
    Viganò M, Lampertico P (2011) Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 11(3):285–300PubMedCrossRefGoogle Scholar
  11. 11.
    Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41(10):1100–1104PubMedCrossRefGoogle Scholar
  12. 12.
    Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10):1105–1109PubMedCrossRefGoogle Scholar
  13. 13.
    Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL (2012) Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 142(3):513–520.e1PubMedCrossRefGoogle Scholar
  14. 14.
    Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH (2011) Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 16(5):629–637PubMedCrossRefGoogle Scholar
  15. 15.
    Wu X, Xin Z, Zhu X, Pan L, Li Z, Li H, Liu Y (2012) Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 93(2):297–300PubMedCrossRefGoogle Scholar
  16. 16.
    Brouwer WP, Arends P, Rijkborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Örmeci N, Akarca US, Flisiak R, Hansen B, Boonstra A, Janssen HLA; for the PARC Study Group (2013) Polymorphisms near the IL28B gene are not associated with response to peginterferon in HBeAg-negative chronic hepatitis B patients. J Hepatol 58:S299CrossRefGoogle Scholar
  17. 17.
    Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M (2013) IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 57(3):890–896PubMedCrossRefGoogle Scholar
  18. 18.
    Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R, Visvanathan K, Hammond R, Iser D, Rusli F, Sievert W, Desmond PV, Bowden DS, Thompson AJ (2013) IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. J Gastroenterol Hepatol 28(5):861–866PubMedCrossRefGoogle Scholar
  19. 19.
    Boglione L, Cusato J, Allegra S, Esposito I, Patti F, Cariti G, Di Perri G, D’Avolio A (2014) Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res 102:35–43PubMedCrossRefGoogle Scholar
  20. 20.
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399–401PubMedCrossRefGoogle Scholar
  21. 21.
    Lampertico P, Galmozzi E, Colombo M (2013) Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype. Hepatology 57(3):1283–1284PubMedCrossRefGoogle Scholar
  22. 22.
    Slusarczyk J, Białkowska J, Bucholc B, Wiatrzyk A, Górska P, Jabłkowski M (2006) HBV genotypes among patients with chronic hepatitis B in the area of central Poland. Przegl Epidemiol 60(3):555–561PubMedGoogle Scholar
  23. 23.
    Deterding K, Constantinescu I, Nedelcu FD, Gervain J, Nemecek V, Srtunecky O, Vince A, Grgurevic I, Bielawski KP, Zalewska M, Bock T, Ambrozaitis A, Stanczak J, Takács M, Chulanov V, Slusarczyk J, Drazd’áková M, Wiegand J, Cornberg M, Manns MP, Wedemeyer H (2008) Prevalence of HBV genotypes in Central and Eastern Europe. J Med Virol 80(10):1707–1711PubMedCrossRefGoogle Scholar
  24. 24.
    Bielawski KP, Dybikowska A, Lisowska-Charmuszko U, Stalke P, Gregorowicz K, Trocha H, Podhajska A (2004) Distribution of HBV genotypes and mutants among hepatitis B infected patients from northern Poland. Int J Mol Med 14(2):301–304PubMedGoogle Scholar
  25. 25.
    Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T (2012) Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 55(6):1700–1710PubMedCrossRefGoogle Scholar
  26. 26.
    Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, Buchbinder S, Carrington M, Thio CL (2010) IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 202(11):1749–1753PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Papatheodoridis G, Gatselis N, Goulis I, Karatapanis S, Deutsch M, Mimidis K, Drakoulis C, Akriviadis EA, Dalekos GN (2013) IL28B polymorphisms as predictors of response to peginterferon-alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 58(Suppl):686AGoogle Scholar
  28. 28.
    de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, Koot M, Jansen PL, Beld MG, Lopatin U, Reesink HW (2012) Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol 47(4):475–481PubMedCrossRefGoogle Scholar
  29. 29.
    Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group (2007) Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56(5):699–705PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ, Mok TS (2008) High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 26(2):177–182PubMedCrossRefGoogle Scholar
  31. 31.
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65–73PubMedCrossRefGoogle Scholar
  32. 32.
    Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S; Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group (2009) Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136(7):2169–2179.e1–4PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • K. Domagalski
    • 1
  • M. Pawłowska
    • 2
  • A. Zaleśna
    • 2
  • M. Tyczyno
    • 2
  • M. Skorupa-Kłaput
    • 3
  • A. Tretyn
    • 3
  • W. Halota
    • 2
  1. 1.Centre for Modern Interdisciplinary TechnologiesNicolaus Copernicus UniversityToruńPoland
  2. 2.Department of Infectious Diseases and Hepatology, Collegium MedicumNicolaus Copernicus UniversityBydgoszczPoland
  3. 3.Department of Plant Physiology and BiotechnologyNicolaus Copernicus UniversityToruńPoland

Personalised recommendations